Top 15 Lowest P/E Ratios of the S&P 500 in 2025

Page 7 of 14

8. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E Ratio: 7.97

Number of Hedge Fund Holders: 76

Bristol-Myers Squibb Company (NYSE:BMY) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 4, Scotiabank lifted its price target on the stock to $53 from $43, while maintaining a Sector Perform rating for its shares, citing Wall Street’s ‘modest expectations’ for the company’s pipeline.

The firm said that results of several clinical trials were expected in 2026, which have not received much attention from investors yet. However, Scotiabank believes these have a significant risk or reward potential and could lead to a significant upside if the outcomes are favorable.

The adjustment follows Goldman Sachs’ update on Bristol-Myers Squibb Company (NYSE:BMY) earlier in the month on December 2, when it raised its price target for the stock to $57 from $51 and kept a Neutral rating on its shares.

Based on the recommendations and price targets from 27 analysts, the stock has a consensus Hold rating and a one-year average share price target of $53.41 as of December 5, representing an upside potential of 2.4%.

In other news, on December 3, Bristol-Myers Squibb Company (NYSE:BMY) said it would expand its ADEPT-2 study of the Alzheimer’s psychosis drug Cobenfy to additional patients after irregularities were observed at certain study sites. Trial results from the program are expected to be declared by the end of 2026.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company engaged in the discovery and development of innovative treatments for several serious diseases.

Page 7 of 14